PF-00610355

DB11871InvestigationalSmall molecule

PF-00610355 has been used in trials studying the treatment of Lung Disease, Moxifloxacin, Pulmonary Disease, Asthma, Bronchial, and Bronchial Diseases, among others.

Mechanism: Pharmacologically active on Beta-2 adrenergic receptor
Curator reviewed
Formula / weight: C₃₄H₃₉N₃O₆S · 617.76 g/mol (avg)
Code names: PF - 00610355 · PF-610355

Resolves to

Compound

UNIIZH5SMU97AJCAS862541-45-5ChEMBLCHEMBL1240967PubChem11505444

Structure

InChIKeyYPHDIMUXXABSSO-YTTGMZPUSA-NSMILESCC(C)(CC1=CC=CC(CC(=O)NCC2=CC=CC(=C2)C2=CC=C(O)C=C2)=C1)NC[C@H](O)C1=CC=C(O)C(NS(C)(=O)=O)=C1

Targets

P07550ADRB2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

789Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with PF-00610355, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account